Biology · 2023
Metabolic and Body Composition Changes in Ice Hockey Players Using an Ergogenic Drug (Cytoflavin).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zaborova Victoria, Kurshev Vladislav, Kryuchkova Kira, Anokhina Valeria, Malakhovskiy Vladimir, Morozova Vera, Sysoeva Veronika, Zimatore Giovanna, Bonavolontà Valerio, Guidetti Laura, Dronina Yuliya, Kravtsova Elena, Shestakov Dmitry, Gurevich Konstantin, Heinrich Katie M
Аннотация
BACKGROUND AND OBJECTIVES: In ice hockey, the major physical workload comes from acceleration in all planes of motion and transitions between skating trajectories. Hockey players' anthropometric characteristics correlate with performance. In team sports, the use of ergogenic drugs for recovery is relevant to avoid athletes' overtraining. It is very important to protect athletes' health and allow them to maintain high-performance levels. Cytoflavin is an ergogenic drug whose action is based on the combined effects of its active ingredients (succinic acid, inosine, nicotinamide and riboflavin), which are naturally occurring metabolites that stimulate tissue respiration. The study aimed to assess the 6-week Cytoflavin consumption effects on body composition (body weight, body mass index, body fat percentage and bioimpedance phase angle) and aerobic performance.
METHODS: This study included 60 male professional hockey players (aged 19 to 36 years) divided into two groups of 30 subjects: group I (body weight 87.90 ± 7.44 kg, BMI 25.86 ± 2.04 kg/m2) and group II (body weight 87.04 ± 6.22 kg, BMI 25.52 ± 2.38 kg/m2). Athletes in group I received Cytoflavin, whereas athletes in group II did not.
RESULTS: In group I, statistically significant reductions in body weight and body mass index were not observed until 14 and 35 days, respectively. In contrast, in group II, both body weight and BMI significantly decreased both times. Aerobic performance significantly increased in both groups, with significantly greater increases in group I.
CONCLUSIONS: Cytoflavin can be considered an ergogenic drug that improves body composition parameters, especially in the control of weight reduction and improvement in aerobic performance.
METHODS: This study included 60 male professional hockey players (aged 19 to 36 years) divided into two groups of 30 subjects: group I (body weight 87.90 ± 7.44 kg, BMI 25.86 ± 2.04 kg/m2) and group II (body weight 87.04 ± 6.22 kg, BMI 25.52 ± 2.38 kg/m2). Athletes in group I received Cytoflavin, whereas athletes in group II did not.
RESULTS: In group I, statistically significant reductions in body weight and body mass index were not observed until 14 and 35 days, respectively. In contrast, in group II, both body weight and BMI significantly decreased both times. Aerobic performance significantly increased in both groups, with significantly greater increases in group I.
CONCLUSIONS: Cytoflavin can be considered an ergogenic drug that improves body composition parameters, especially in the control of weight reduction and improvement in aerobic performance.